Clinical Trial Update: ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of ACX-362E (ibezapolstat) for recurrent Clostridioides difficile infection is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• ACX-362E (ibezapolstat)

Snippet

Sponsor: Acurx Pharmaceuticals Inc. | Conditions: Clostridium Difficile Infection Recurrence | Phase 2 | Status: NOT_YET_RECRUITING